On March 6, the U.S. Food and Drug Administration (FDA) announced the approval of Surfaxin (lucinactant) for the prevention of respiratory distress syndrome in premature infants. Read more.
FDA approves Surfaxin to prevent respiratory distress syndrome in premature infants.
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.
NurseLine Newsletter
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.
